Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2014-02-14 Major Shareholding Noti…
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
13G OVAS 2-14-2014
Major Shareholding Notification
2014-02-14 English
Major Shareholding Notification 2014
Major Shareholding Notification
2014-02-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 7, 2014. The content specifically details the resignation of a Vice President of Finance and the appointment of a new principal financial officer. This type of information pertains to changes in the company's board of directors or senior management. There is no financial data, earnings information, or report publication mentioned. The document length is 3554 characters, which is relatively short and focused on management changes. Therefore, the appropriate classification is Board/Management Information (MANG).
2014-02-07 English
OVASCIENCE, INC. SCHEDULE 13G, AMENDMENT 1
Major Shareholding Notification
2014-02-06 English
4
Director's Dealing
2014-01-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 13, 2014, by OvaScience, Inc. It includes an Item 8.01 'Other Events' section announcing an update on pipeline advancements and commercial plans, and references a press release attached as Exhibit 99.1. The document is short (2556 characters) and primarily serves as a current report to announce a corporate event or update, not a full financial report or detailed filing. It does not contain financial statements or detailed financial data. Therefore, it fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2014-01-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.